Stock LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-18 pm EDT 		5-day change 1st Jan Change
3.351 USD +0.63% Intraday chart for Lixte Biotechnology Holdings, Inc. -0.86% +42.60%
Mar. 27 Sector Update: Health Care Stocks Advance Late Afternoon MT
Mar. 27 Top Midday Gainers MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Top Midday Gainers
MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data
MT
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
AQ
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal
CI
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
AQ
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
AQ
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
AQ
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
CI
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
AQ
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma
CI
Top Premarket Decliners
MT
Lixte Biotechnology : Investor Presentation - November 2023
PU
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
AQ
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
CI
Certain Warrants of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIXT Stock
  4. News Lixte Biotechnology Holdings, Inc.